Innate Invariant NKT Cells Recognize *Mycobacterium tuberculosis*–Infected Macrophages, Produce Interferon-γ, and Kill Intracellular Bacteria

Isabel Sada-Ovalle¹,², Asako Chiba¹, Adaena Gonzales¹, Michael B. Brenner¹, Samuel M. Behar¹

¹ Division of Rheumatology, Immunology, and Allergy, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, ²Immunoochemistry Department, National Institute of Respiratory Diseases, Mexico City, Mexico

Abstract

Cellular immunity to *Mycobacterium tuberculosis* (*Mtb*) requires a coordinated response between the innate and adaptive arms of the immune system, resulting in a type 1 cytokine response, which is associated with control of infection. The contribution of innate lymphocytes to immunity against *Mtb* remains controversial. We established an in vitro model to address whether innate lymphocytes have a role in immunity against *Mtb* infection.

Following *Mtb* infection, NK cells become activated and are early and rapid producers of interferon-γ (IFN-γ), a cytokine critical for the activation of macrophages (*Mφ*) [2,3]. However, mouse models in which NK cells are defective or are depleted in vivo have failed to show that NK cells are essential for immunity to tuberculosis [3]. Similarly, γδ T cells are frequently activated by a variety of pathogens including *Mtb* [4]. Mice lacking γδ T cells succumb more rapidly than control mice following intravenous challenge with virulent *Mtb*; however, such a difference has not been observed following infection by the aerosol route [5,6]. Although γδ T cells may not be required for optimum control of bacterial replication following pulmonary infection, γδ T cells may obscure the contribution of other immune mechanisms. Factors such as inoculum size, *Mtb* strain virulence, and experimental variability limit the dynamic range of the end points measured and reduce the capacity to detect subtle defects in immunity. We established an in vitro model to address whether innate lymphocytes have a role in immunity against *Mtb*. In our model, splenocytes obtained from uninfected mice are cultured with primary *Mtb* infected with virulent *Mtb*. Under these conditions, splenocytes secrete IFN-γ,
Author Summary

Host resistance to Mycobacterium tuberculosis (Mtb) requires a coordinated response by the different components of the immune system. We established an in vitro model to study the contribution of innate lymphocytes to immunity against Mtb. When co-cultured with Mtb-infected macrophages, splenocytes from uninfected mice become activated and suppress bacterial replication. By fractionating the different splenocyte cell populations, we discovered that the invariant NKT (iNKT) cell is essential for suppressing intracellular bacterial replication. iNKT cells, which are conserved in rodents and humans, recognize lipids presented by the antigen-presenting molecule CD1d. While we had previously shown that iNKT cell-deficient mice are not more susceptible to tuberculosis, a potential contribution of iNKT cells during the early phase of immunity may have been masked. To address this issue, we showed that highly purified iNKT cells were sufficient to reduce the lung bacterial burden of mice infected with virulent Mtb. This is the first evidence that CD1d-restricted iNKT cells play a physiological role in mediating protection against aerosol Mtb infection in vivo. Thus, by being an early producer of interferon-γ and suppressing intracellular bacterial growth, iNKT cells function as an important part of the early immune response against Mtb.

Results

Splenocytes from Naive Mice Are a Source of Innate IFN-γ and Restrict Growth of Mtb

Elicited peritoneal Mφ were infected with virulent Mtb for 2 hrs as described in the Methods. The Mφ were cultured overnight after infection, and the next day splenocytes obtained from uninfected C57BL/6 (B6) mice were added. After 24 hrs, IL-12 was detected in the supernatant of infected macrophages irrespective of whether splenocytes were added (Figure 1A). In contrast, IFN-γ was detected only in the supernatant from cocultures of splenocytes and infected Mφ, but not from cultures of splenocytes and uninfected Mφ, nor from infected Mφ alone (Figure 1B).

Three days after the addition of the splenocytes, the number of bacteria contained in the cultures was determined. Compared to infected Mφ cultured alone, the addition of splenocytes led to a 54.5% reduction of Mtb CFU (p<0.0001) (Figure 1C). The precise number of bacteria used to infect the Mφ varied between experiments; therefore, to compare experiments, the data was normalized based on the CFU recovered from infected Mφ 4 days after in vitro infection. This analysis revealed that co-culture of naive splenocytes with infected Mφ led to a 44.1±3.1% (n=18 experiments) reduction in mycobacterial growth compared to infected Mφ cultured alone (Figure 1D). Thus, infected Mφ stimulated the production of IFN-γ by naive splenocytes which correlated with a reduction in the number of Mtb recovered from the cultures.

Suppression of Mycobacterial Growth by Splenocytes Is T Cell–Dependent

The main cellular source of IFN-γ is NK and T cells. To determine the cellular basis for control of Mtb replication, we first determined whether splenocytes from uninfected RAG−/− mice, which lack mature B and T lymphocytes but are enriched for NK cells, could restrict bacterial growth. Compared to splenocytes from uninfected B6 mice, splenocytes from B6 RAG−/− mice were unable to reduce mycobacterial CFU (p=0.23) (Figure 2A).

The inability of RAG−/− splenocytes to limit Mtb growth argues that a B or T lymphocyte subset is required to restrict bacterial replication. To determine which cell type was critical in this process, splenic T cells (CD90+) and B cells (CD19+) were purified from naive B6 mice. Purified B cells (CD19+), or splenocytes depleted of T cells (CD90−) were unable to control mycobacterial growth (p>0.05, compared to infected Mφ alone) (Figure 2B). In contrast, purified T cells (CD90+), or splenocytes enriched in T cells (CD19−) very efficiently controlled bacterial growth (p<0.05) (Figure 2B). The increased activity of T cells to control bacterial growth compared to total splenocytes (p<0.05), strongly suggests that suppression of mycobacterial replication is dependent on T cells.

To further characterize the T cell subset that restricts bacterial replication, T cells from spleens of naive B6 mice were fractionated. We compared the ability of purified CD4+ and CD8− cells to reduce CFU. Our results showed that both CD4+ and CD8− cells control bacterial growth (Figure 2C). However,
the anti-mycobacterial activity of CD4+ and CD4− cells was not significantly different. While this result may indicate that either CD4+ or CD8+ T cells can restrict mycobacterial growth, this effect could be dependent upon NKT cells. Although NKT cells account for only a small fraction of total splenocytes, they can have either a CD4+ or CD8− phenotype, and thus, they would be predicted to be present in both the CD4+ and CD4− T cell compartment.

Recognition of Infected Mϕ by CD1d-Restricted iNKT Cells Is Required for the Suppression of Mycobacterial Growth

To test the hypothesis that inhibition of mycobacterial growth is dependent on CD1d-restricted NKT cells, we tested whether splenocytes from two different mouse strains that lack NKT cells could reduce Mtb CFU. CD1d−/− mice lack both invariant and diverse CD1d-restricted NKT cells; in contrast, Jz281−/− mice are deficient only in invariant NKT (iNKT) cells. Naïve splenocytes from naïve CD1d−/−, Jz281−/− or WT mice were cocultured with infected Mϕ and bacterial growth was measured 3 days later. Compared to WT splenocytes, both CD1d−/− and Jz281−/− splenocytes had lost the capacity to control mycobacterial replication (p>0.05 compared to Mϕ alone). Thus, the ability of splenocytes to limit mycobacterial growth is dependent upon iNKT cells (Figure 3A).

The requirement for iNKT cells in the control of mycobacterial growth raised the possibility that these cells were being activated by the infected Mϕ. Both CD1d-dependent and CD1d-independent mechanisms of iNKT cell activation have been described [15]. Infection can lead to CD1d-dependent iNKT cell activation if there is cognate recognition of microbial antigens, or if the pathogen induces sufficient cytokine production to drive the activation of self-reactive iNKT cells [16]. To determine whether the expression of CD1d by the infected Mϕ was required for control of bacterial replication by iNKT cells, Mϕ from CD1d−/− and B6 WT mice were infected in vitro. Naïve splenocytes were added and bacterial growth was measured 3 days later. Naïve splenocytes co-cultured with infected WT Mϕ reduced the Mtb CFU by 62% (p<0.05) (Figure 3B). In contrast, no CFU reduction was observed when the same splenocytes were cultured with CD1d−/− Mϕ (p, NS). This shows that CD1d expression by the infected Mϕ is required for the control of Mtb growth by splenocytes. Thus, CD1d-restricted recognition between the infected Mϕ and the iNKT cell is required for suppression of bacterial replication.

Both iNKT Cells and Conventional T Cells Become Activated When Cultured with Mtb-Infected Mϕ

Activated iNKT cells modulate the activity of other cells including B and T cells, NK cells, granulocytes, and DC. Therefore, while the anti-mycobacterial activity of naïve splenocytes may depend on iNKT cells, iNKT cells may not be sufficient to mediate bacterial growth restriction. To determine what other cell types become activated following culture with Mtb-infected Mϕ, we measured the expression of the CD69 activation marker 24 hrs after coculture of splenocytes with uninfected or Mtb-infected Mϕ. CD69 expression remained low on CD4+, CD8+, and iNKT cells cultured with uninfected Mϕ (Figure 4, top row). In contrast, within 24 hrs after culture with infected Mϕ, iNKT cells upregulated CD69 expression from 0.4% to 25.2% (Figure 4, bottom row). Similarly, CD69 expression increased on CD4+ T cells from 0.9% to 5.2%, and on CD8+ T cells from 0.3% to 7.9% (Figure 4). Splenocytes from CD1d−/− mice were analyzed under these same conditions. Just as with the WT splenocytes, upregulation of CD69 by CD4+ and CD8+ T cells was observed within 24 hrs after culture with infected Mϕ (data not shown). These results show that Mtb-infected Mϕ stimulate the activation of iNKT cells, CD4+ and CD8+ T cells. However, the induction of CD69 expression by conventional CD4+ and CD8+ T cells is CD1d-independent.

iNKT Cell Effector Function Is Dependent on IL-12 and IL-18 Cytokine-Driven Activation

Following Mtb infection, a variety of cytokines are made by infected Mϕ, including IL-12 and IL-18, which can drive the antigen-independent production of IFN-γ by T cells. To
determine whether IL-12 and IL-18 secreted by infected Mφ are required for iNKT cell activation, antibodies to anti-IL-12p40, anti-IL-18, or both were added to co-cultures of naïve splenocytes and infected Mφ.

Culture of splenocytes with infected Mφ led to the production of γ interferon (IFN-γ) and nitric oxide (NO) in the culture supernatant (Figure 5A and 5B). These are important mediators of anti-mycobacterial immunity, and IFN-γ is required for optimal induction of inducible nitric oxide synthase (iNOS), which leads to intracellular production of NO, an important effector molecule that ultimately suppresses the growth of Mtb. Blockade of IL-12p40 or IL-18 significantly abrogated the secretion of IFN-γ in these cultures (Figure 5A). A predictable consequence was a reduction in NO production (Figure 5B).

In agreement with the reduced secretion of IFN-γ and NO, blockade of IL-12 or IL-18 abrogated control of bacterial replication. Thus, iNKT cell activation and control of the bacterial replication was dependent on both IL-12 p40 and IL-18 (Figure 5C).

iNKT Cells Are Sufficient To Kill Intracellular Mtb

The results presented above show that the ability of splenocytes to restrict mycobacterial growth is dependent upon iNKT cells. Because iNKT cells have both direct effector and immunoregulatory functions, we next determined whether iNKT cells were sufficient to restrict the growth of Mtb or whether this effect was mediated by cross-talk, which activates other cell types to produce IFN-γ. To assess whether invariant NKT cells can directly kill Mtb,
splenocytes from uninfected B6 mice or short-term iNKT cell lines were cocultured with infected Mφ.

On day 1 after infection, 7,663 CFU were recovered after the lysis of Mtb-infected Mφ. After three additional days of culture, the CFU increased 3-fold to 22,587. As previously observed, the addition of naive splenocytes on day 1 reduced the number of CFU recovered on day 4 to 9,992 CFU, which represents a 56% reduction compared to infected Mφ alone on day 4 (p<0.05) (Figure 6A). As addition of splenocytes reduced the number of CFU close to, but not below the day 1 value, this reduction represents a suppression of bacterial growth but not killing of Mtb.

Addition of purified iNKT cells reduced the CFU by 88%, demonstrating that iNKT cells are sufficient to mediate this antibacterial effect (p<0.05, compared to infected Mφ alone, day 4) (Figure 6A). Interestingly, the number of bacteria recovered was lower even than the number of Mtb recovered on day 1 (68.4% reduction, p<0.05 compared to infected Mφ alone, day 1) (Figure 4). Thus, not only are iNKT cells necessary and sufficient to restrict intracellular Mtb replication, but they have the capacity kill Mtb.

Next, we determined whether a physiological number of NKT cells cultured with infected Mφ could have a similar effect. iNKT cells account for 2–5% of splenocytes in B6 mice, which means that 100,000–250,000 iNKT cells are present among the five million splenocytes added to the infected Mφ. Thus, we varied the number of pure iNKT cells from five million to as few as 75,000. Interestingly, fewer iNKT cells led to higher IFN-γ production (Figure 6B). The number of bacteria remaining in the cultures was determined on day 3, and even the presence of 75,000 iNKT cells were able to limit bacterial replication and did so more efficiently than splenocytes (Figure 6C). Again it was observed that after infected Mφ were cultured with purified iNKT cells for 3 days, fewer bacteria remained than were present when the iNKT cells were added (Mφ day 1), suggesting that the iNKT cells induced bacterial killing (Figure 6C).

**iNKT Cells Reduce the Bacterial Burden of Mtb-Infected Mice**

Our in vitro results show that Mtb-infected Mφ induce iNKT cell activation, which leads to macrophage production of NO, which is associated with the suppression of bacterial growth and perhaps kill Mtb. We have previously shown that CD1d<sup>−/−</sup> mice are not more susceptible to Mtb infection [7]. To reevaluate the potential beneficial role of iNKT cells during Mtb infection, NKT cells were transferred into irradiated C57BL/6 mice, which were
infected with virulent *Mtb* by the aerosol route. Three weeks later the mice were sacrificed and the CFU in the lung and spleen determined. A significant CFU reduction was observed in both the lung and spleen (Figure 7).

To further assess the protective capacity of iNKT cells, we transferred splenic lymphocytes from uninfected C57BL/6 mice that were enriched for iNKT cells by depleting cells expressing CD8 and CD62L (data not shown). As a control, the same cell population was obtained from J281/− mice, which lack iNKT cells. The cells obtained from WT mice provided protection to irradiated recipient mice against *Mtb* (Figure 7). In contrast, the cells obtained from J281/− mice were unable to transfer protection. These data show that primary iNKT cells that had never been activated in vitro are capable of protecting immunocompromised host from *Mtb*.

**Discussion**

We find that *Mtb*-infected Mφ stimulate IFN-γ production by splenocytes. Since the splenocytes are obtained from uninfected mice that have no previous exposure to *Mtb* and thus are not “immune” with respect to *Mtb* antigens, their IFN-γ production must represent activation of an innate pathway. Surprisingly, the production of IFN-γ is dependent on iNKT cells, a minor subset of T cells that are present in the spleen at a frequency of ~1%. The biology of iNKT cells has been well described during the past decade: they are CD1d-restricted T cells that express an invariant TCR, rapidly produce cytokines when activated, and modulate a variety of immune phenomena [17–19].

How do *Mtb*-infected Mφ activate iNKT cells? There are several models of how CD1d-restricted T cells become activated. Presentation of microbial lipid antigen has been described for certain infectious agents [20–23], and although *Mtb* antigens are known for group 1 CD1, it’s possible that CD1d presents *Mtb* ligands, our study does not directly address this possibility. In our model, iNKT cell effector function is dependent upon CD1d expression by the infected Mφ, indicating that CD1d recognition is required. Whether a microbial antigen or an endogenous self-lipid antigen is recognized is not certain. Both IL-12p40 and IL-18 are required for the iNKT cell effector function we observe. Thus, our data is consistent with iNKT cell recognition of a self or microbial antigen and costimulation by IL-12 and IL-18, two cytokines which are produced by *Mtb*-infected Mφ. Not only does IL-12p40 and IL-12p35 form the heterodimeric cytokine IL-12p70, but IL-12p40 also pairs with IL-23p19, to form the cytokine IL-23. Since IL-23 is induced by mycobacterial infection of Mφ [24,25], an alternate interpretation of our data is that IL-23 has a role in iNKT cell activation. Following iNKT cell activation, IFN-γ is rapidly induced and early stimulates infected Mφ to produce iNOS. This leads to the accumulation of NO, which is associated with suppression of bacterial growth.

Many studies have described how iNKT cells contribute to microbial immunity (reviewed in [15,26,27]). iNKT cells are frequently activated early during infection and secrete IFN-γ, which can have an immunomodulatory role. The use of CD1d−/− and J281−/− mice has clearly revealed that iNKT cells can either exacerbate or ameliorate the outcome of infection. In addition, pharmacological activation of iNKT cells with the synthetic ligand αGalCer often enhances host resistance to infection. iNKT cell use several mechanisms to modify host immunity. These include induction of DC maturation, secondary activation of effector cells (NK cells) or recruitment of inflammatory cells to the site of infection [PMNs] [28–32]. However, this is the first example of iNKT cells having a direct effector function against a microbial pathogen.

Whether CD1d-restricted T cells are required for immunity against *Mtb* has been partially addressed by several studies. Both CD1d−/− and J281−/− mice have been infected with virulent *Mtb* by both the IV and aerosol route. All studies to date have found that the absence of CD1d-restricted T cells do not alter the outcome to tuberculosis infection in the mouse model [7–11]. Nevertheless, treatment of mice with αGalCer, which specifically activates iNKT cells, significantly prolongs the survival of infected mice [14]. In fact, a single dose of αGalCer given the day after infection prolongs the survival of mice, an endpoint quite remote from its administration. Thus, it may be that iNKT cells are not activated optimally in mycobacterial infection but they can alter the long-term outcome of infection when pharmacologically activated. A physiological role for this T cell subset early during infection has been suggested by Szalay et al, who found that treatment of *Mtb*-infected mice with anti-CD1 mAb diminished control of bacterial replication early after IV infection and correlated with reduced IFN-γ and TNF production by *Mtb* antigen stimulated splenocytes [33]. While another study found that anti-CD1d mAb treatment did not worsen the pulmonary *Mtb* burden following low dose aerosol infection, early time points were not examined [8]. Our results are consistent with an early innate role for iNKT cells in controlling *Mtb* infection.

Why are CD1d−/− mice, which lack the iNKT cell subset, no more susceptible than WT mice to *Mtb* infection? There may be insufficient numbers of resident iNKT cells in the lung to mediate an anti-mycobacterial effect early during the course of infection. Although we observed that only a few iNKT cells are needed to suppress *Mtb* replication, the statistical probability of finding an iNKT cell and an infected Mφ in the same alveoli is low. In contrast, once infection is established, iNKT cells are recruited to the lung and Mφ upregulate cell surface CD1d [34]; however, this is coincident with the appearance of conventional T cells in the lung, which may overshadow the contribution of CD1d-restricted T cells. If IFN-γ production is the key function of CD1d-restricted T cells, CD1d and J281 ko mice may lack a phenotype because this function can be mediated by other cell types. Cytokines such as...
as IL-12 and IL-18 can drive IFN-γ production by γδ T cells, NK cells, and memory CD8 T cells independently of cognate antigen recognition. Finally, an intriguing observation is the development of iNKT cell anergy following BCG infection [35] and other bacterial infections [36]. If iNKT cell anergy were to develop during Mtb infection, then iNKT cells would appear to make little or no contribution to immunity against Mtb infection. We speculate that the basis of the protective effect of αGalCer lies in its ability to activate iNKT cells before anergy develops.

We established an in vitro model to study innate cellular mechanisms of immunity against intracellular Mtb. We find that macrophages infected with virulent Mtb stimulate the IFN-γ production by non-immune splenocytes, which inhibits bacterial replication. These cellular events are entirely dependent on iNKT cells forcing us to re-examine the role of CD1d-restricted iNKT cells in vivo. Using a primary iNKT cell line, we show that iNKT cells provide protection against low dose aerosol Mtb infection. These data demonstrate that iNKT cells have a physiological role in limiting Mtb infection by acting directly as effector T cells. These findings provide a rationale for understanding how immunomodulation of CD1d-restricted T cells during Mtb infection can have a role in the adjuvant therapy of tuberculosis.

Methods

Mice

C57BL/6 (B6) mice were obtained from The Jackson Laboratory. CD1d knockout (CD1d<sup>−/−</sup>) mice on the B6 background were kindly provided by Mark Exley [37]. Jx281 knockout (Jx281<sup>−/−</sup>) mice were provided by M. Taniguchi (Riken, Japan) [38]. Female mice, 7–8 weeks of age, were used in all experiments. Mice were bred and maintained under specific pathogen-free conditions and were used in a protocol approved by the Dana Farber Cancer Institute.

Antibodies and CD1d-PBS57 Tetramers

The following FITC-, PE-, PEG7-, allophycocyanin-, and PerCP-conjugated anti-mouse mAbs were purchased from BD Pharmingen: anti-CD8 (PerCP), anti-CD3 (APC), anti-CD69 (PEG7), and anti-CD4 (FITC). Anti-mouse IL-18 was purchased from MBL, anti-mouse IL-12/IL-23 p40, mouse IgG1 and IgG2A isotype controls were purchased from RD systems. CD1d-PBS57 and control PE-conjugated tetramers were provided by the National Institute of Allergy and Infectious Diseases Tetrramer Facility (Emory University Vaccine Center, Atlanta, GA).

Peritoneal Mφ and In Vitro Culture

Peritoneal exudate cells were harvested by intraperitoneal lavage 4 days after intraperitoneal injection of sterile 3% thioglycolate medium [34]. Mφ were purified in a two steps protocol: B cells were depleted using anti-CD19-microbeads followed by positive selection of Mφ with CD11b-microbeads (Miltenyi Biotec). The purified cells were >95% F4/80<sup>−</sup>CD11b<sup>+</sup>, as determined by flow cytometry. Purified Mφ (1 × 10<sup>5</sup>) were seeded into 24-well plates in complete RPMI 1640 medium (Invitrogen Life Technologies) supplemented with 10% fetal calf serum (HyClone), penicillin/streptomycin, L-glutamine, sodium-pyruvate, 2-ME, nonessential amino acids, essential amino acids, and HEPES buffer (all from Gibco). Recombinant mouse IFN-γ (US Biological) was used at the concentrations indicated.

Bacteria and In Vitro Infections

Virulent Mtb (H37Rv) was grown to mid-log phase in Middlebrook 7H9 medium containing 10% albumin/dextrose/catalase enrichment (BD Biosciences). Bacteria were opsonized for 2 minutes using RPMI 1640 medium with 2% human serum (Gemini Bio-Products), 10% FBS, and 0.05% Tween 80 and then washed twice with complete medium without antibiotics. Bacteria were passed through a 5-μm syringe filter (Millipore), counted in a Petroff-Hauser chamber and added to enriched Mφ at different multiplicity of infection (MOI) as indicated. The length on infection was 2 hr for all experiments. Infected Mφ were cultured overnight before the addition of splenocytes or purified cell subsets (see below). In some experiments, infected Mφ were cultured overnight in the presence of rIFN-γ (2.5 units/ml). The next day all wells were washed twice with RPMI medium without antibiotics.

Splenocytes and Cell Enrichment

Spleens were aseptically removed and mechanically homogenized with a 3-ml syringe plunger. Erythrocytes were lysed with RBC lysis buffer (1 mM KHCO3, 0.15 M NaCl and 0.1 mM sodium-EDTA [pH 7.3]). Cells were washed and viability determined using trypan blue. Splenocytes were resuspended in complete RPMI 1640 medium and unless otherwise specified, 5 × 10<sup>6</sup> splenocytes/well were added to cultures of infected Mφ in 24-well plates. T cells (Thyl<sup>−</sup>), B cells (CD19<sup>+</sup>) and CD4<sup>+</sup> T cells were enriched using microbeads (Miltenyi Biotec, Auburn, CA). Enriched NKT cells were prepared by depleting CD8<sup>+</sup> and CD2DL<sup>+</sup> cells from splenocytes using microbeads, and contained 12-15% tetramer<sup>+</sup> T cells.

NKT Cell Line

T cells were negatively isolated from splenocytes of Vα14-Jα281 Tg mice by using the Pan T cell isolation kit (Miltenyi Biotec). NKT cells staining with the APC labeled mouse CD1d tetramer were enriched using microbeads (Miltenyi Biotec). Bone marrow-derived dendritic cells (BM-DC) were grown from bone marrow progenitors by culture for 6 days in the presence of granulocyte-monocyte colony stimulating factor (10 ng/ml) and IL-4 (1 ng/ml) (R&D Systems) in complete RPMI medium (RPMI supplemented with L-glutamine and penicillin/streptomycin; Life Technologies) containing 10% FBS (Hyline laboratories). BM-DCs were pulsed with αGalCer at 100 ng/ml for 24 hr at 37°C and then irradiated at 3400 rad. 2 × 10<sup>6</sup> NKT cells were cultured with 2 × 10<sup>5</sup> αGalCer-pulsed BM-DCs per well in 24 well plates in complete RPMI 1640 medium. 3–5 days later, mIL-2 (10 U/ml) (R&D Systems) and mIL-7 (10 ng/ml) (PeproTech) were added in the medium. NKT cell lines were re-stimulated with αGalCer-loaded BM-DCs every 2–3 weeks. These cells were used for both in vitro and in vivo experiments.

Blocking Experiments

Cytokine function was blocked by addition of azide-free, low-endotoxin anti-mouse cytokine-specific mAbs. Infected Mφ were co-cultured with naive splenocytes at a ratio of 5:1 in the presence or absence of antibodies specific for IL-12 (10 μg/ml, clone C17.8, R & D) and IL-18 (10 μg/ml, clone 93-10C, MBL) or isotype-matched control mAb. On day 4 after the infection supernatants and cells were recovered to analyze IFN-γ and NO production, and bacterial growth.

CFU Determination

Bacterial growth was quantified 24 hrs after Mφ infection (hereafter referred to as day 1) and 72 hr after coculture with naive splenocytes or splenocyte cell fractions (day 4). After removing the
culture supernatant, cells were lysed by adding distilled water for 3 min and plating 10-fold dilutions on Middlebrook 7H11 agar plates. In some experiments, the number of CFU contained in the supernatant was also determined. The number of bacteria contained in the supernatant was <10% of the cell-associated CFU, and this was true whether or not splenocytes or other cell fractions were added to the infected Mφ. The number of colonies was counted 3 weeks after incubation at 37°C in a humidified CO2 atmosphere.

Cytokine Detection

Culture supernatants were assayed for IFN-γ and IL-12p40 by standard sandwich ELISA. All Ab pairs and standards were purchased from BD PharMingen, and ELISAs were done in accordance with the manufacturer’s instructions. Samples were read at 405 nm on SoftMax Pro ELISA analysis software (Molecular Devices). IFN-γ and IL-12p40 were quantified by comparison with the appropriate recombinant standard (purchased from BD PharMingen).

NO Production

Supernatants were harvested after 24 hrs of coculture and NO production was measured using the Griess reaction. Briefly, 100 μl of culture supernatants were incubated with an equal volume of commercial Griess reagent (Sigma-Aldrich) for 5 min at room temperature, and the absorbance was measured at 490 nm. Serially diluted NaNO2 of known concentration was used as a standard to calculate the amount of NO2 found in the supernatant [39].

Flow Cytometry

Changes in the phenotype of cells 24 hrs after coculture with infected Mφ was determined by multiparametric flow cytometry. Recovered cells were resuspended in FACS buffer (2% FCS, 2 mM sodium azide in PBS). To inhibit nonspecific staining, cells were incubated with 25 μg/ml of anti-FcγRII/III Ab (2.4G2) for 10 min at 4°C, washed, and then stained with fluorochrome-conjugated isotype-matched control IgG or Abs specific for mouse cellular markers. Cells were also stained with CD1d-PBS57 tetramer in FACS buffer for 15–20 min at 4°C, and then washed and fixed in 1% paraformaldehyde overnight. Data was collected using a FACSCanto (BD Biosciences) and analyzed with FlowJo (Tree Star).

NKT Cell Adoptive Transfer into Mtb-Infected Recipient Mice

An adoptive transfer system was used to analyze the ability of NKT cells to mediate protection during pulmonary tuberculous infection. B6 mice were sublethally irradiated with 600 rads from a cesium-137 source. The next day, the mice were infected with virulent Mtb (Erdman strain) via the aerosol route as described previously [40]. Invariant NKT cells (5×10^3/mouse) or enriched splenic NKT cells (10×10^3/mouse) were injected via the tail vein into the infected B6 mice. Three weeks after infection and adoptive transfer, the mice were euthanized and their left lung and spleen were aseptically removed and individually homogenized in 0.9% NaCl-0.02% Tween 80 with a Mini-Bead-Beater-8 (BioSpec Products, Bartlesville, OK). Viable bacteria were enumerated by plating 10-fold serial dilutions of organ homogenates onto 7H11 agar plates (Remel). Colonies were counted after 3 weeks of incubation at 37°C.

Statistical Analysis

Data are shown as mean±standard deviation (SD). Unpaired student’s t-test was used to compare two groups and one way analysis of variance (ANOVA) when more than two groups were compared. A level of p <0.05 was accepted as statistically significant. For the in vivo experiments, CFU were log10 transformed before statistical testing using the non-parametric Mann-Whitney test. Analysis was performed using Prism 5.0 software (GraphPad Software, Inc., San Diego, CA).

Acknowledgments

The authors are grateful to our colleagues Dr. Markus Skold and Dr. Manfred Briegl for their helpful advice and thoughtful discussions.

Author Contributions

Conceived and designed the experiments: ISO AC SMB. Performed the experiments: ISO AC AG SMB. Analyzed the data: ISO SMB. Contributed reagents/materials/analysis tools: ISO AC MBB. Wrote the paper: ISO SMB.

References

1. Bendelac A, Bonville M, Kearney JF (2001) Autoreactivity by design: Innate B and T lymphocytes. Nat Rev Immunol 1: 177–186.
2. Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hieny S, et al. (2006) NK Cell-Derived IFN-γ (gamma) Differentially Regulates In innate Resistance and Neutrophil Response In T Cell-Deficient Hosts Infected with Mycobacterium tuberculosis. J Immunol 177: 7086–7093.
3. Junqueira-Kipnis AP, Kipnis A, Jamieson A, Juarrero MG, Diefenbach A, et al. (2003) NK cells respond to pulmonary infection with Mycobacterium tuberculosis, but play a minimal role in protection. J Immunol 171: 6039–6045.
4. Behar SM, Boom WH (2008) Unconventional T Cells. In: Kaufmann SHE, Britton WJ, eds. Handbook of Tuberculosis. Weinheim: Wiley-VCH. pp 97–104.
5. Tupin E, Kinjo Y, Kronenberg M (2007) The unique role of natural killer T cells to mediate protection during pulmonary tuberculosis infection. Infect Immun 75: 6302–6309.
6. Sousa AO, Mazzuccaro RJ, Russell RG, Lee FK, Turner OC, et al. (2000) Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculous infection in mice. Proc Natl Acad Sci U S A 97: 4204–4208.
7. Kawai K, Kinjo Y, Uezu K, Yaza S, Miyagi K, et al. (2002) Minimal contribution of Valpha14 natural killer T cells to Th1 response and host resistance against mycobacterial infection in mice. Microb Immunol 46: 207–210.
8. Mempel T, Ronet C, Suarez F, Gilevson M, Pazo G, et al. (2002) Natural Killer T Cells Restricted by the Monomorphic MHC Class 1b CD1d Molecules Behave Like Inflammatory Cells. J Immunol 168: 365–371.
9. Apostolou I, Takahama Y, Belmant C, Kawano T, Huere M, et al. (1999) Murine natural killer T(NKT) cells [correction of natural killer cells] contribute to the granulomatous reaction caused by mycobacterial cell walls. Proc Natl Acad Sci U S A 96: 5141–5146.
10. Chackerian A, Alt J, Perera V, Behar SM (2002) Activation of NKT cells protects mice from tuberculous infection. Infect Immun 70: 6302–6309.
11. Tapin E, Kinjo Y, Kronenberg M (2007) The unique role of natural killer T cells in the response to mycobacteria. Nat Rev Microbiol 5: 403–417.
12. Barral DC, Brenner MB (2007) CD1d antigen presentation: How it works. Nat Rev Immunol 7: 929–941.
13. Briegl M, Brenner MB (2004) CD1α: Antigen Presentation and T Cell Function. Annu Rev Immunol 22: 817–890.
18. Bendelac A, Savage PB, Teyton L (2007) The biology of NKT cells. Annu Rev Immunol 25: 297–336.
19. Kronenberg M (2005) Toward an understanding of NKT cell biology: Progress and paradoxes. Annu Rev Immunol 23: 877–900.
20. Amprey JL, In JS, Turco SJ, Murray HW, Illarionov PA, et al. (2004) A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 200: 895–904.
21. Mattner J, Debord KL, Imsad N, Geff RD, Cann C III, et al. (2005) Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434: 523–529.
22. Kinjo Y (2005) Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434: 520–525.
23. Striram V, Du W, Gervay-Hague J, Bratkiewicz RR (2005) Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT cells. Eur J Immunol 35: 1692–1701.
24. Jang S, Uzelac A, Solgane P (2006) Distinct chemokine and cytokine gene expression pattern of murine dendritic cells and macrophages in response to Mycobacterium tuberculosis infection. J Leukoc Biol 80: 1264–1270.
25. Chackerian AA, Chen SJ, Brodie SJ, Mattson JD, McClanahan TK, et al. (2006) Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection. Infect Immun 74: 6992–6999.
26. Skold M, Behar SM (2003) Role of CD1d-restricted NKT cells in microbial immunity. Infect Immun 71: 3447–3455.
27. Behar SM, Porcelli SA (2007) CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol 314: 215–250.
28. Fujii S, Shimizu K, Hennini H, Steinman RM (2007) Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunity 26: 183–190.
29. Carnaud C, Lee D, Donnaro O, Park SH, Beavis A, et al. (1999) Cutting edge: Cross-talk between cells of the innate immune system. NKT cells rapidly activate NK cells. J Immunol 163: 4647–4650.
30. Shimizu K, Goto A, Fukuji M, Taniguchi M, Fujii S (2007) Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice. J Immunol 178: 2853–2861.
31. Snydy MJ, Wallace ME, Natt SL, Yagita H, Godfrey D, et al. (2005) Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 201: 1973–1983.
32. Nakamatsu M, Yamamoto N, Hata M, Nakasone C, Kinjo T, et al. (2007) Role of interferon-gamma in Valpha14(+) natural killer T cell-mediated host defense against Streptococcus pneumoniae infection in murine lungs. Microbes Infect 9: 364–374.
33. Szalay G, Ladel CH, Blum C, Brossay L, Kronenberg M, et al. (1999) Cutting edge: Anti-CD1d monoclonal antibody treatment reverses the production patterns of TGF-beta 2 and TH1 cytokines and ameliorates listeriosis in mice. J Immunol 162: 6955–6958.
34. Skold M, Xiong X, Ilarionov PA, Besra GS, Behar SM (2003) Interplay of cytokines and microbial signals in regulation of CD1d expression and NKT cell activation. J Immunol 175: 3394–3399.
35. Chiba A, Dascher CC, Besra GS, Brenner MB (2008) Rapid NKT Cell Responses Are Self-Terminating during the Course of Microbial Infection. J Immunol 181: 2292–2302.
36. Kim S, Lalani S, Parekh-VV, Vincent TL, Wu L, et al. (2008) Impact of bacteria on the phenotype, functions, and therapeutic activities of invariant NKT cells in mice. J Clin Invest 118: 2301–2315.
37. Edey MA, Bigley NJ, Cheng O, Shaulov A, Taher SM, et al. (2003) Innate immune response to encephalomyocarditis virus infection mediated by CD1d. Immunology 110: 519–526.
38. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. (1997) Requirement for valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278: 1623–1626.
39. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131–138.
40. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM (2002) Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity. Infect Immun 70: 4501–4509.